Quantcast
Last updated on April 21, 2014 at 10:25 EDT

Latest abdominal aortic aneurysm Stories

2011-07-12 08:00:00

IRVINE, Calif., July 12, 2011 /PRNewswire/ -- Endologix, Inc. (NASDAQ: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its second quarter 2011 financial results, which will take place on Thursday, July 21, 2011 after the close of the market. Endologix will hold a conference call on Thursday, July 21, 2011 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for...

2011-06-15 08:00:00

IRVINE, Calif., June 15, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its next generation product, the AFX(TM) Endovascular AAA System, for the treatment of abdominal aortic aneurysms (AAA). Endologix is introducing AFX at the Annual Meeting of the Society for Vascular Surgery (SVS), which is taking place June...

2011-05-06 11:45:00

IRVINE, Calif., May 6, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 2011 Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV. Event: 2011 Bank of America Merrill Lynch Health Care Conference Date: Tuesday, May 10, 2011 Time: 3:40 p.m. PT An audio Web cast...

2011-04-21 15:05:00

IRVINE, Calif., April 21, 2011 /PRNewswire/ -- Endologix, Inc. (NASDAQ: ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2011. John McDermott, Endologix President and Chief Executive Officer, said, "First quarter revenue grew by 28% year-over-year, reflecting our continued momentum in the marketplace as the innovation leader in the endovascular treatment of abdominal aortic aneurysms (AAA)....

2011-04-21 10:51:00

TEMPLE, Texas, April 21, 2011 /PRNewswire/ -- Scott & White Healthcare today teleconferenced one of the world's first live international surgical procedures to repair an abdominal aortic aneurysm to conference attendees in Sao Paolo, Brazil. The meeting, CICE (Current Issues in Comparative Education) 2011, is one of the globe's largest vascular surgery events and includes over 2,000 attendees. The procedure demonstrated the use of an endograft device called a repositionable...

2011-04-13 15:00:00

IRVINE, Calif., April 13, 2011 /PRNewswire/ -- Endologix, Inc. (NASDAQ: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its first quarter 2011 financial results, which will take place on Thursday, April 21, 2011 after the close of the market. Endologix will hold a conference call on Thursday, April 21, 2011 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for domestic...

2011-03-07 15:01:00

IRVINE, Calif., March 7, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the ROTH 23rd Annual OC Growth Stock Conference in Laguna Niguel, CA. Event: ROTH 23rd Annual OC Growth Stock Conference Date: Monday, March 14, 2011 Time: 4:30 p.m. PT An audio Web cast of the Company's presentation...

2011-02-15 10:51:00

IRVINE, Calif., Feb. 15, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the presentation of the initial clinical results from the PEVAR Trial at the 2011 iCON (International Congress of Endovascular Specialists) annual meeting in Scottsdale, Arizona. Among 33 patients enrolled in the Roll-In phase of the trial, technical success rates of 97% (access) and 100% (endovascular repair) have been achieved, with...

2011-01-31 08:00:00

IRVINE, Calif., Jan. 31, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the publication of favorable clinical results for the Nellix technology for the endovascular repair of abdominal aortic aneurysm (EVAR). The peer-reviewed article reported initial results from the international multicenter clinical trial, with successful aneurysm exclusion in all patients, and no late aneurysm or device-related...

2011-01-20 15:00:00

IRVINE, Calif., Jan. 20, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2010 financial results, which will take place on Tuesday, February 22, 2011 after the close of the market. Endologix will hold a conference call on Tuesday, February 22, 2011 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. The dial-in numbers are (877)...